Enterprise Value
334.2M
Cash
698M
Avg Qtr Burn
-10.38M
Short % of Float
9.44%
Insider Ownership
28.00%
Institutional Own.
43.45%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bebtelovimab (LY-CoV1404) Details COVID-19 | Approved Update | |
Bamlanivimab (LY-CoV555) Details COVID-19 | Approved Quarterly sales |